Smart dosing could tame toxic TB drug side effects
NCT ID NCT07477119
First seen Mar 21, 2026 · Last updated May 02, 2026 · Updated 5 times
Summary
This study aims to see if adjusting the dose of the antibiotic linezolid based on regular blood tests can reduce harmful side effects in people being treated for multidrug-resistant tuberculosis (MDR-TB). About 150 adults and teens in Guinea will receive the standard BPaL regimen, but half will have their linezolid dose personalized using therapeutic drug monitoring. The goal is to keep drug levels in a safe range and lower the risk of nerve damage and other serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THERAPEUTIC DRUG MONITORING (TDM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre de Santé de Tombolia
Conakry, Guinea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.